Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) PT at $5.50

Design Therapeutics, Inc. (NASDAQ:DSGNGet Free Report) has received a consensus recommendation of “Hold” from the seven analysts that are presently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $5.50.

Several brokerages recently commented on DSGN. Wedbush reiterated a “neutral” rating and set a $5.00 target price on shares of Design Therapeutics in a report on Wednesday. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 target price on shares of Design Therapeutics in a report on Wednesday.

View Our Latest Research Report on Design Therapeutics

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Legal & General Group Plc grew its position in shares of Design Therapeutics by 28.0% in the 2nd quarter. Legal & General Group Plc now owns 3,247 shares of the company’s stock worth $45,000 after acquiring an additional 711 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Design Therapeutics by 11.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,173 shares of the company’s stock worth $96,000 after acquiring an additional 1,546 shares in the last quarter. Bank of America Corp DE grew its position in shares of Design Therapeutics by 4.1% in the 1st quarter. Bank of America Corp DE now owns 57,199 shares of the company’s stock worth $924,000 after acquiring an additional 2,262 shares in the last quarter. American International Group Inc. boosted its position in Design Therapeutics by 20.1% during the 2nd quarter. American International Group Inc. now owns 15,859 shares of the company’s stock valued at $222,000 after purchasing an additional 2,657 shares during the period. Finally, Tower Research Capital LLC TRC boosted its position in Design Therapeutics by 48.7% during the 3rd quarter. Tower Research Capital LLC TRC now owns 9,010 shares of the company’s stock valued at $151,000 after purchasing an additional 2,951 shares during the period. Institutional investors and hedge funds own 69.47% of the company’s stock.

Design Therapeutics Stock Performance

Shares of NASDAQ:DSGN opened at $3.80 on Wednesday. The company has a market cap of $214.66 million, a P/E ratio of -3.17 and a beta of 1.72. Design Therapeutics has a one year low of $1.94 and a one year high of $8.47. The business’s 50-day simple moving average is $2.57 and its 200 day simple moving average is $2.44.

About Design Therapeutics

(Get Free Report

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.

Read More

Analyst Recommendations for Design Therapeutics (NASDAQ:DSGN)

Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.